Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity
Authors
Keywords
-
Journal
CANCER
Volume 122, Issue 9, Pages 1398-1407
Publisher
Wiley
Online
2016-03-22
DOI
10.1002/cncr.29933
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Association of lymphocytosis following treatment with dasatinib with response and outcome.
- (2017) C. A. Schiffer et al. JOURNAL OF CLINICAL ONCOLOGY
- Dasatinib promotes Th1-type responses in granzyme B expressing T-cells
- (2014) Anna Kreutzman et al. OncoImmunology
- Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia
- (2013) H. L. M. Rajala et al. BLOOD
- Rapid and sustained increase of large granular lymphocytes and rare cytomegalovirus reactivation during dasatinib treatment in chronic myelogenous leukemia patients
- (2012) Hideo Tanaka et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy
- (2012) S Mustjoki et al. LEUKEMIA
- SomaticSTAT3Mutations in Large Granular Lymphocytic Leukemia
- (2012) Hanna L.M. Koskela et al. NEW ENGLAND JOURNAL OF MEDICINE
- Retrospective multicenter study on the development of peripheral lymphocytosis following second-line dasatinib therapy for chronic myeloid leukemia
- (2011) Su Jin Lee et al. AMERICAN JOURNAL OF HEMATOLOGY
- Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy
- (2010) A. Kreutzman et al. BLOOD
- Dasatinib: A potent SRC inhibitor in clinical development for the treatment of solid tumors
- (2010) John Araujo et al. CANCER TREATMENT REVIEWS
- Safe switching from dasatinib to nilotinib after a 1-month off-drug period for persistent pleural effusion in patients with chronic myelogenous leukemia in chronic phase
- (2010) Yasunobu Nagata et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion
- (2010) Yasunobu Nagata et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Prevalence of large granular lymphocytosis in patients with chronic myelogenous leukemia (CML) treated with dasatinib
- (2010) Jason N. Valent et al. LEUKEMIA RESEARCH
- Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
- (2010) Hagop Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up
- (2009) H. Kantarjian et al. BLOOD
- Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion
- (2009) Kimmo Porkka et al. CANCER
- Dasatinib inhibits the secretion of TNF-α following TLR stimulation in vitro and in vivo
- (2009) Cara K. Fraser et al. EXPERIMENTAL HEMATOLOGY
- Abl tyrosine kinases in T-cell signaling
- (2009) Jing Jin Gu et al. IMMUNOLOGICAL REVIEWS
- Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy
- (2009) S Mustjoki et al. LEUKEMIA
- Chronic myeloid leukemia in the tyrosine kinase inhibitor era: What is the best therapy?
- (2009) Alfonso Quintás-Cardama et al. Current Oncology Reports
- Dasatinib inhibits the proliferation and function of CD4+CD25+regulatory T cells
- (2008) Fei Fei et al. BRITISH JOURNAL OF HAEMATOLOGY
- The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro
- (2008) Stephen Blake et al. CLINICAL IMMUNOLOGY
- Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens
- (2008) Fei Fei et al. EXPERIMENTAL HEMATOLOGY
- Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia
- (2008) D. H. Kim et al. HAEMATOLOGICA
- Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia
- (2008) Neil P. Shah et al. JOURNAL OF CLINICAL ONCOLOGY
- Therapy Options in Imatinib Failures
- (2008) P. Ramirez et al. ONCOLOGIST
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started